SEC Form 4 · accession 0001640455-18-000103
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberlee C Drapkin
Officer — CFO and Treasurer
Period of report
Aug 27, 2018
Accepted (ET)
Aug 28, 2018 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 27, 2018 | M | 12,700 | $2.36 | A | 27,100 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.36 | Aug 27, 2018 | M | 12,700 | D | — | Aug 25, 2025 | Common Stock | 12,700 | 213,514 | D |
Explanation of responses
- F125% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter.